NR3C2 and diabetic kidney disease: A four‐pillar treatment approach for slowing the progression of diabetic kidney disease is suggested, comprising a renin–angiotensin–system (RAS) inhibitor, a sodium–glucose cotransporter 2 inhibitor, a glucagon‐like peptide 1 receptor agonist, and the nonsteroidal mineralocorticoid receptor antagonist finerenone.